Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Lonza Group Ltd ( (CH:LONN) ).
Lonza Group Ltd has announced its 2024 comparative financials under the new One Lonza organizational structure, effective from April 2025. This structure includes three CDMO Business Platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities, while the Capsules & Health Ingredients business remains unchanged. The updated financials aim to provide investors with comparable figures ahead of the Half-Year 2025 results, reflecting the company’s strategic focus on its core business areas.
The most recent analyst rating on (CH:LONN) stock is a Buy with a CHF645.00 price target. To see the full list of analyst forecasts on Lonza Group Ltd stock, see the CH:LONN Stock Forecast page.
More about Lonza Group Ltd
Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs) dedicated to serving the healthcare industry. The company operates globally, working with pharmaceutical and biotech companies to develop therapies using advanced science, technology, and manufacturing processes. In 2024, Lonza reported sales of CHF 6.6 billion and a CORE EBITDA of CHF 1.9 billion.
Average Trading Volume: 182,971
Current Market Cap: CHF39.38B
Find detailed analytics on LONN stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue